The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Toscafund selling is not good news, they've held this for years
there was a lot of dilution at time of merger, they haven't reported a NAV per share for months' discount is not what it appears
what i like is directors have skin in the game - always helps
I hope that they RNS now we have FDA approval we can deliver ---- machines to hospitals and UNi's etc etc
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214375
FDA approval with a couple of hundred orders lined up would be nice they've had the time
so Sajy when you say Yeeh ha does that mean yippy ai aye cos you sound like a cowboy ?or what your really saying is we've heard nothing know nothing but the fact we've heard nothing yet is great sounds like your deluded, im happy to give it a whirl and hold for the news
PJT12 or investors like a long term gamble ?
thanks you for your wonderful insights you are clearly in a different league
Sajy, really ? expecting apologies on a BB, come on get over yourself, everything's a punt you haven't proved anything to anyone. Rene's been up over 40p and down sub 30p since your wonderful tip. POLX is undervalued in my opinion everyone should buy and Rene is more of a punt but i like Phil Banks approach
ok Sajy lets hope you're right
Sajy, i hold both have held Rene for years since woodford first invested so down a packet, but i topped up a couple of months back at 30p i watched the investor meet, kind of gathered that they'd like to buy, quite impressed with Catherine Isted. would be interesting to know what the transfer of technology to Fosun is worth any views maybe take this to the RENE board?
that's only 28 years from now, though i suspect Gas demand will continue beyond that
Payment for staff salaries was RNS'd as per my previous post
RNS Number : 3326Y
ReNeuron Group plc
13 January 2022
("ReNeuron" or the "Company")
Additional agreement with Fosun Pharma for CTX
Progression with Fosun Pharma underscores commitment to CTX stroke disability programme
ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that following on from the original Fosun Pharma ("Fosun") licensing agreement announced on 9 April 2019, the Company has signed an additional agreement with Fosun, on 5 January 2022, setting out the first steps in the potential technology transfer of the CTX drug product for the stroke disability programme.
The agreement allows for £320,000 to be invoiced on signing with further payments expected, based on services and CTX cell bank vials to be supplied by ReNeuron in the future, although these are contingent on signing a supplemental payment terms agreement which is currently under discussion.
ReNeuron will update the market further once agreement on these terms have been reached.
Olav Hellebø, Chief Executive Officer, commented: "We are pleased to announce progress in the technology transfer of the CTX drug product to Fosun and believe this highlights the commitment Fosun has to the programme in Greater China."
ENDS
Contacts:
ReNeuron
www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer
Via Walbrook PR
Catherine Isted, Chief Financial Officer
What he said was Fosun have already provided funding for staff salaries and that already been RNS'd, he went on to say there is a transfer of technology agreement being put in place and certain matters are still being addressed with regards to this but when it is complete is will be RNS'sd, which he expects to happen within a couple of months, hopefully there will be further moneys due in relation to this and maybe this is why they are in a closed period, one can only speculate
a wry smile when asked if they would be buying shares, but couldn't possibly comment, overall a positive presentation i thought
thats uncanny did you know something?